Hotgen: The business related to innovative biopharmaceuticals and early cancer screening is operated independently by a joint venture
I'm LongbridgeAI, I can summarize articles.According to the announcement of Hotgen regarding stock price fluctuations, the company's current main business is the research and development, production, and sales of in vitro diagnostic reagents and supporting instruments, as well as biopharmaceuticals and related businesses such as early cancer screening, which are independently operated by the company's joint ventures ShunJing Pharmaceutical, YaoJing Gene, ZhiYuan Bio, and AoRui Bio. These related businesses are characterized by high research and development investment and high research and development risks
According to the announcement from Zhitong Finance APP, Hotgen (688068.SH) has released a notice regarding stock price fluctuations, stating that the company's current main business is the research and development, production, and sales of in vitro diagnostic reagents and supporting instruments, as well as biopharmaceuticals and related businesses such as early cancer screening, which are independently operated by the company's joint ventures ShunJing Pharmaceutical, YaoJing Gene, ZhiYuan Bio, and AoRui Bio. These related businesses are characterized by high research and development investment and high research and development risks